HIV protease inhibitor with pharmacokinetic booster

This page covers all HIV protease inhibitor with pharmacokinetic booster drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HIV protease, HIV protease; CYP3A4.

Targets

HIV protease · HIV protease; CYP3A4

Marketed (2)

• Active comparator: DRV/cb · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Infectious Disease
  DRV/c (darunavir boosted with cobicistat) is a protease inhibitor combined with a pharmacokinetic booster that blocks HIV protease to prevent viral replication.
• Darunavir/Cobicistat (FDC) · Janssen Scientific Affairs, LLC · Infectious Disease
  Darunavir is a protease inhibitor that blocks HIV protease to prevent viral replication, while cobicistat is a boosting agent that inhibits CYP3A4 to increase darunavir levels.

Patent intelligence

• hiv protease inhibitor with pharmacokinetic booster patent landscape — aggregated cliff calendar, attackable patents, originator estates